Abstract: Provided is a carbon dioxide fluidity control device comprising, a sample preparation tank, a high-pressure stirring unit, a reciprocating plunger pump and a booster pump, wherein the stirring unit comprises one or more high-pressure stirring tanks, each provided with an atomizing spray probe and a piston, wherein a discharge port of the sample preparation tank is connected to the atomizing spray probe via a plunger pump, which is connected to the piston to push the piston to reciprocate; the booster pump is connected to the high-pressure stirring tanks to provide supercritical carbon dioxide to the high-pressure stirring tank; and a discharge port of the high-pressure stirring tanks is connected to an oilfield well group. Provided is a carbon dioxide fluidity control method using the device, comprising mixing surfactants and nanoparticles with heated carbon dioxide, and injecting a microemulsion of supercritical carbon dioxide and nano-silicon dioxide into an oilfield well group.

Abstract: The present disclosure relates to a drug combination for treating non-small cell lung cancer, in particular to uses of ergosterol combined with gefitinib, and belongs to the technical field of biomedicine. In the present disclosure, the mechanism of action that ergosterol (ERG) combined with gefitinib (GEF) induces apoptosis of non-small cell lung cancer (NSCLC) cells is firstly studied; then an RGG cyclic peptide/R8 peptide modified ERG combined with GEF active drug-loaded targeted liposome delivery system (RGD/R8-ERG/GEF-LIP) is constructed; and the RGD/R8-ERG/GEF-LIP is prepared into a freeze-dried powder to improve stability, quality evaluation and preliminary evaluation of in vitro anti-lung cancer effects are conducted, and a nude mouse lung cancer xenograft model is established for conducting preliminary pharmacodynamic research and in vivo targeting research.

Abstract: The present disclosure relates to a drug combination for treating non-small cell lung cancer, in particular to uses of ergosterol combined with gefitinib, and belongs to the technical field of biomedicine. In the present disclosure, the mechanism of action that ergosterol (ERG) combined with gefitinib (GEF) induces apoptosis of non-small cell lung cancer (NSCLC) cells is firstly studied; then an RGG cyclic peptide/R8 peptide modified ERG combined with GEF active drug-loaded targeted liposome delivery system (RGD/R8-ERG/GEF-LIP) is constructed; and the RGD/R8-ERG/GEF-LIP is prepared into a freeze-dried powder to improve stability, quality evaluation and preliminary evaluation of in vitro anti-lung cancer effects are conducted, and a nude mouse lung cancer xenograft model is established for conducting preliminary pharmacodynamic research and in vivo targeting research.

Abstract: The presently disclosed subject matter is directed to an RGD peptide and penetrating peptide R8 co-modified ergosterol and cisplatin active drug-loading liposome that is prepared by means of the incubation of an ergosterol and cisplatin active drug-loading liposome, RGD cyclic peptide, and penetrating peptide R8 in a water bath. The ergosterol and cisplatin active drug-loading liposome is prepared from an ergosterol liposome and a cisplatin solution serving as the raw materials. The ergosterol liposome is prepared from 8 wt % to 15 wt % ergosterol and 85 wt % to 92 wt % liposomes, and the liposomes consist of lecithin and cholesterol.